CH EPL (R5)
1.0.0-ci-build - ci-build Switzerland flag

CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ci-build built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions

: Indication 10030247 - XML Representation

Raw xml | Download


<ClinicalUseDefinition xmlns="http://hl7.org/fhir">
  <id value="IND-10030247"/>
  <meta>
    <profile
             value="http://fhir.ch/ig/ch-epl/StructureDefinition/ch-idmp-clinicalusedefinition-indication"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ClinicalUseDefinition IND-10030247</b></p><a name="IND-10030247"> </a><a name="hcIND-10030247"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-ch-idmp-clinicalusedefinition-indication.html">CH IDMP ClinicalUseDefinition Indication</a></p></div><p><b>type</b>: Indication</p><p><b>subject</b>: <a href="MedicinalProductDefinition-Estalis-Transdermalpatch.html">MedicinalProductDefinition: extension = Transdermal patch; identifier = http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MPID#CH-7601001029439-5470402; indication = Klimakterische Beschwerden: Behandlung der Symptome des Östrogenmangels infolge der natürlichen oder künstlichen Menopause bei nicht-hysterektomierten Frauen.
Osteoporoseprophylaxe: Vorbeugung oder Verzögerung einer durch Östrogenmangel induzierten Osteoporose bei postmenopausalen Frauen mit hohem Frakturrisiko, für die eine Behandlung mit anderen zur Prävention der Osteoporose zugelassenen Arzneimitteln nicht in Frage kommt, oder bei Frauen die gleichzeitig an behandlungsbedürftigen Symptomen des Östrogenmangels leiden.; legalStatusOfSupply = Medicinal product subject to medical or veterinary prescription (B); additionalMonitoringIndicator = No Warning; pediatricUseIndicator = Not authorised for the treatment in children; classification = norethisterone and estrogen,NA KAS art. 12 para. 5 TPLO,Synthetic,Originator product</a></p><blockquote><p><b>indication</b></p><h3>DiseaseSymptomProcedures</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://www.meddra.org 10030247}">Oestrogenmangel</span></td></tr></table><h3>Comorbidities</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://www.meddra.org 10027308}">Menopause</span></td></tr></table><h3>IntendedEffects</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://spor.ema.europa.eu/v1/lists/200000003186 200000003192}">preventive</span></td></tr></table></blockquote></div>
  </text>
  <type value="indication"/>
  <subject>🔗 
    <reference value="MedicinalProductDefinition/Estalis-Transdermalpatch"/>
  </subject>
  <indication>
    <diseaseSymptomProcedure>
      <concept>
        <coding>
          <system value="https://www.meddra.org"/>
          <code value="10030247"/>
          <display value="Oestrogenmangel"/>
        </coding>
      </concept>
    </diseaseSymptomProcedure>
    <comorbidity>
      <concept>
        <coding>
          <system value="https://www.meddra.org"/>
          <code value="10027308"/>
          <display value="Menopause"/>
        </coding>
      </concept>
    </comorbidity>
    <intendedEffect>
      <concept>
        <coding>
          <system value="http://spor.ema.europa.eu/v1/lists/200000003186"/>
          <code value="200000003192"/>
          <display value="preventive"/>
        </coding>
      </concept>
    </intendedEffect>
  </indication>
</ClinicalUseDefinition>